I Love Drug Stocks

Money troubles can sometimes ruin a good relationship. However, if you choose pharmaceutical stocks like Johnson and Johnson (NYSE: JNJ  ) or GlaxoSmithKline (NYSE: GSK  ) as your significant investing others, you'll get companies that steadily grow their top-line results, even when the economy is in a recession.

It would be great if people only got sick when the economy was booming, but illness pays the business cycle no mind. While other sectors of the stock market, like transportation or tech stocks, may be sinking during a recession, large-cap pharmaceutical and biotech stocks are much more recession-proof, since their demand and earnings fluctuate far less.

I'm not just in love with pharmaceutical and biotech stocks for their independence. Where else besides the technology industry will you find stocks like Amgen (Nasdaq: AMGN  ) or ImClone Systems (Nasdaq: IMCL  ) that can be 50-baggers in less than 20 years?

Small development-stage drug stocks are not for the faint of heart. If you can't possibly stand losing 75% or more on your shares in one day, stay clear. But some of these companies' larger blue-chip brethren have a place in almost any portfolio. Even investors with an income- or value-oriented bent will find many drug stocks suitable for consumption, given some of the larger firms' juicy 3%-plus annual dividend yields. No matter how you like to invest, or what your macroeconomic outlook may be, there's always a drug stock that will be a good match for you. That's why all investors should leave a special place in their heart for drug stocks on Valentine's Day.

What's sending Fools' hearts aflutter? Go back to our intro page to see what else we have a crush on.

GlaxoSmithKline and Johnson & Johnson are Income Investor recommendations. Discover our full lineup of dynamic dividend-paying stocks with a free 30-day trial subscription.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (35)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 521798, ~/Articles/ArticleHandler.aspx, 10/21/2016 12:46:30 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,115.89 -46.46 -0.26%
S&P 500 2,137.45 -3.89 -0.18%
NASD 5,249.57 7.74 0.15%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 12:30 PM
AMGN $159.25 Down -2.25 -1.39%
Amgen CAPS Rating: ****
GSK $41.12 Down -0.31 -0.75%
GlaxoSmithKline CAPS Rating: ***
IMCL $69.99 Down +0.00 +0.00%
ImClone Systems CAPS Rating: **
JNJ $113.65 Down -1.23 -1.07%
Johnson and Johnso… CAPS Rating: ****